News
HSDT
5.83
+4.11%
0.23
HSDT Stock Earnings: Helius Medical Tech Beats EPS, Misses Revenue for Q4 2023
Helius Medical Tech reported earnings per share of -$1.47 for the fourth quarter of 2023. The company reported revenue of $134,000. This was 46.40% worse than the analyst estimate for revenue in the same period. Helius medical tech reported results for the quarter.
Investorplace · 6h ago
Helius Medical Technologies Inc reports results for the quarter ended in December - Earnings Summary
Helius Medical Technologies Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $1.47 per share. Revenue fell 52.5% to $134.00 million from the same quarter last year. The mean expectation of three analysts was for the company to lose $3.77 a share.
Reuters · 10h ago
Helius Medical Tech Q4 2023 GAAP EPS $(1.47) Beats $(3.77) Estimate, Sales $134.000K Miss $246.333K Estimate
Helius Medical Tech reported quarterly losses of $1.47 per share. The company reported quarterly sales of $134.000 thousand which missed the analyst consensus estimate of $246.333 thousand by 45.60%. The company also reported a 52.48 percent decrease in sales for the same period.
Benzinga · 10h ago
Recap: Helius Medical Tech Q4 Earnings
Helius Medical Tech reported its Q4 earnings on March 28. The company beat estimates by 61.0%. Revenue was down $148 thousand from the same period last year. Last quarter the company beat on EPS by $0.51 and the share price dropped 3.0% the next day.
Benzinga · 10h ago
*Helius Medical Tech 4Q Rev $134,000 >HSDT
Dow Jones · 11h ago
*Helius Medical Tech 4Q Loss/Shr $1.47 >HSDT
Dow Jones · 11h ago
Helius Medical Technologies GAAP EPS of -$1.47 beats by $2.30, revenue of $0.13M misses by $0.12M
Helius Medical Technologies Q4 GAAP EPS of -$1.47 beats by $2.30, revenue of $0.13M misses by $ 0.12M. The company's Q4 revenue was down 53.6% from the same period last year.
Seeking Alpha · 11h ago
After-Hours Earnings Report for March 28, 2024 : ACHV, ACNT, AREC, AXDX, CPTN, CURV, DARE, DNMR, DYAI, FORA, HSDT, INLX
NASDAQ · 13h ago
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
Helius Medical Technologies, Inc. Announces results for the quarter and full year ended December 31, 2023. Company to host call at 4:30pm today. Helius is a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits.
Barchart · 16h ago
Earnings Scheduled For March 28, 2024
Universal Stainless is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. Walgreens Boots Alliance is likely to report earnings for its fourth quarter. Companies Reporting Before The Bell include Shimmick and Universal Stainless. Companies reporting after the bell include INmune Bio and Oxford Industries.
Benzinga · 21h ago
Helius Medical Tech's Earnings Outlook
Helius Medical Tech is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Analysts estimate the company will report an earnings per share of $-3.77. Last quarter the company beat EPS by $0.51. Shares of Helius medical tech were trading at $5.58 as of March 26.
Benzinga · 1d ago
Helius Medical Technologies Inc <HSDT.OQ> expected to post a loss of $3.77 a share - Earnings Preview
Helius Medical Technologies Inc expected to post a loss of $3.77 a share. The company is expected to report a 12.6% decrease in quarterly revenue to $246.33 thousand from $282 thousand a year ago.
Reuters · 2d ago
Weekly Report: what happened at HSDT last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at HSDT last week (0311-0315)?
Weekly Report · 03/18 11:07
Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
Helius Medical Technologies, Inc. Will release its fourth quarter and full year 2023 financial results on March 28, 2024. The Company is a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits. The company will release results after the market closes.
Barchart · 03/15 06:05
Helius Medical Technologies, Inc. Initiates Open-Label Study For Registrational Program In Stroke
Enrollment of at least ten patients at Brooks Rehabilitation will begin this month. Study will evaluate the use of Portable Neuromodulation Stimulator (PoNS®) for gait and balance deficits in chronic stroke survivors. Results will support efforts to achieve U.S. Authorization under PoNS's breakthrough designation for stroke.
Benzinga · 03/12 13:05
Weekly Report: what happened at HSDT last week (0304-0308)?
Weekly Report · 03/11 11:04
Helius Medical Tech Is Maintained at Buy by Roth MKM
Dow Jones · 03/05 18:34
Roth MKM Maintains Buy on Helius Medical Tech, Adjusts Price Target To $24
Benzinga · 03/05 18:27
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Bitdeer Technologies Group shares jumped 10.2% to $7.45 on Monday. The company announced successful testing of its SEAL01 Bitcoin mining chip. BitFuFu Inc. Shares jumped 107% in the mid-day session. Macy's, Inc. And MGE also rose amid strength in the price of Bitcoin.
Benzinga · 03/04 18:29
More
Webull provides a variety of real-time HSDT stock news. You can receive the latest news about Helius Med Technologies Inc through multiple platforms. This information may help you make smarter investment decisions.
About HSDT
Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.